Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a randomized, 6-week sleep laboratory trial - PubMed (original) (raw)
Randomized Controlled Trial
doi: 10.1016/j.sleep.2015.04.001. Epub 2015 Apr 16.
Affiliations
- PMID: 26047892
- DOI: 10.1016/j.sleep.2015.04.001
Randomized Controlled Trial
Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a randomized, 6-week sleep laboratory trial
Neely Ivgy-May et al. Sleep Med. 2015 Jul.
Abstract
Objective: Esmirtazapine (Org 50081), a medication that binds with high affinity to serotonin 5-HT2A and histamine-1 receptors, was evaluated as a potential treatment for insomnia.
Methods: Adults with primary insomnia were treated with esmirtazapine (3.0 or 4.5 mg) or placebo in this 6-week, double-blind, randomized, polysomnography (PSG) study. The end points included wake time after sleep onset (WASO) (primary), latency to persistent sleep, and total sleep time. Patient-reported parameters were also evaluated, including sleep quality and satisfaction with sleep duration. Residual daytime effects and rebound insomnia (sleep parameters during the single-blind placebo run-out week after treatment ended) were also assessed.
Results: Overall, 419 patients were randomized and 366 (87%) completed treatment. The median decrease in PSG WASO (double-blind average) was 20.5 min for placebo, and 52.0 min and 53.6 min for the 3.0- and 4.5-mg esmirtazapine groups, respectively (P < 0.0001 vs. placebo for both doses). Changes in the other PSG parameters and in all patient-reported parameters were also statistically significant with both doses versus placebo. Overall, 35-42% of esmirtazapine-treated patients had adverse events (AEs) versus 29% in the placebo group. AEs were mild or moderate in most esmirtazapine-treated patients. Furthermore, the incidence of AEs leading to discontinuation was low (<8%).
Conclusions: Six weeks of treatment with esmirtazapine was associated with consistent improvements in objective and patient-reported parameters of sleep onset, maintenance, and duration. It was generally well tolerated, and residual daytime effects were minimal and no rebound insomnia was observed.
Keywords: Clinical trial; Esmirtazapine; Insomnia; Polysomnography; Sleep maintenance.
Copyright © 2015. Published by Elsevier B.V.
Similar articles
- Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a 2-week randomized outpatient trial.
Ivgy-May N, Roth T, Ruwe F, Walsh J. Ivgy-May N, et al. Sleep Med. 2015 Jul;16(7):831-7. doi: 10.1016/j.sleep.2015.03.005. Epub 2015 Mar 30. Sleep Med. 2015. PMID: 26047890 Clinical Trial. - A Phase 2 Randomized Dose-Finding Study With Esmirtazapine in Patients With Primary Insomnia.
Ruwe F, IJzerman-Boon P, Roth T, Zammit G, Ivgy-May N. Ruwe F, et al. J Clin Psychopharmacol. 2016 Oct;36(5):457-64. doi: 10.1097/JCP.0000000000000546. J Clin Psychopharmacol. 2016. PMID: 27482970 Clinical Trial. - Treatment of elderly primary insomnia patients with EVT 201 improves sleep initiation, sleep maintenance, and daytime sleepiness.
Walsh JK, Salkeld L, Knowles LJ, Tasker T, Hunneyball IM. Walsh JK, et al. Sleep Med. 2010 Jan;11(1):23-30. doi: 10.1016/j.sleep.2009.07.012. Epub 2009 Nov 28. Sleep Med. 2010. PMID: 19945340 Clinical Trial. - Eszopiclone for the treatment of primary insomnia: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials.
Liang L, Huang Y, Xu R, Wei Y, Xiao L, Wang G. Liang L, et al. Sleep Med. 2019 Oct;62:6-13. doi: 10.1016/j.sleep.2019.03.016. Epub 2019 Apr 6. Sleep Med. 2019. PMID: 31518944 - Histamine-1 receptor antagonism for treatment of insomnia.
Vande Griend JP, Anderson SL. Vande Griend JP, et al. J Am Pharm Assoc (2003). 2012;52(6):e210-9. doi: 10.1331/JAPhA.2012.12051. J Am Pharm Assoc (2003). 2012. PMID: 23229983 Review.
Cited by
- Efficacy, Safety, and Drug-Drug Interactions for Insomnia Therapy in COVID-19 Patients.
Saputra BD, Levita J, Mustarichie R. Saputra BD, et al. J Multidiscip Healthc. 2022 Jan 21;15:137-152. doi: 10.2147/JMDH.S337053. eCollection 2022. J Multidiscip Healthc. 2022. PMID: 35087274 Free PMC article. Review. - The assessment and management of insomnia: an update.
Krystal AD, Prather AA, Ashbrook LH. Krystal AD, et al. World Psychiatry. 2019 Oct;18(3):337-352. doi: 10.1002/wps.20674. World Psychiatry. 2019. PMID: 31496087 Free PMC article. - Alliance for Sleep Clinical Practice Guideline on Switching or Deprescribing Hypnotic Medications for Insomnia.
Watson NF, Benca RM, Krystal AD, McCall WV, Neubauer DN. Watson NF, et al. J Clin Med. 2023 Mar 25;12(7):2493. doi: 10.3390/jcm12072493. J Clin Med. 2023. PMID: 37048577 Free PMC article. Review. - How representative are insomnia clinical trials?
Roehrs T, Verster JC, Koshorek G, Withrow D, Roth T. Roehrs T, et al. Sleep Med. 2018 Nov;51:118-123. doi: 10.1016/j.sleep.2018.06.003. Epub 2018 Jun 26. Sleep Med. 2018. PMID: 30144651 Free PMC article. - Efficacy and safety of esmirtazapine in adult outpatients with chronic primary insomnia: a randomized, double-blind placebo-controlled study and open-label extension.
Ivgy-May N, Hajak G, van Osta G, Braat S, Chang Q, Roth T. Ivgy-May N, et al. J Clin Sleep Med. 2020 Sep 15;16(9):1455-1467. doi: 10.5664/jcsm.8526. J Clin Sleep Med. 2020. PMID: 32351205 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical